ArriVent BioPharma Faces Investigation After Stock Plunge of 56.7% Amid Trial Failure#USA#New_York#ArriVent_BioPharma#NASDAQ_AVBP#firmanertinib
ArriVent BioPharma Faces Investigation After Stock Plunge of 56.7% Amid Trial Failure
ArriVent BioPharma is under investigation following a 56.7% stock drop after their Phase 3 trial for firmonertinib failed. Investors may seek compensation.
third-news.com
October 6, 2026 at 9:53 PM
ArriVent BioPharma Faces Investigation After Stock Plunge of 56.7% Amid Trial Failure#USA#New_York#ArriVent_BioPharma#NASDAQ_AVBP#firmanertinib